Netherlands· NL-38967aede0bb
Mekinist 2 mg filmomhulde tablet
A trametinib product containing trametinibdimethylsulfoxide, registered in Netherlands by Novartis Europharm Limited. The same ATC class is registered in 12 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Trametinib is registered in 12 of 19 countries.
Countries holding a registration under ATC L01EE01 (trametinib), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 7 of them publish a price we can compare per daily dose
Trametinib · ATC L01EE01
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
Price per daily dose
What a daily dose of trametinib costs, country by country.
Normalised to the WHO defined daily dose (2 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Trametinib · price per daily dose (2 mg)
USD · FX 28 Sept 2026
- CH Switzerland$215.55
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- TRAMETINIBDIMETHYLSULFOXIDE
- Manufacturer
- Novartis Europharm Limited
- Country
- Netherlands (NL)
- ATC code
- L01EE01
- ATC class
- Trametinib
- Defined daily dose
- 2 mg, O
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_idEU/1/14/931
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
22 interactions on record for trametinib.
Graded by severity as the source publishes them — 22 moderate. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Trametinib · interactions on record
22 records
- 22 moderate
Most severe, free to view
- FostamatinibB02BX09moderate
- ElagolixH01CC03moderate
- SarecyclineJ01AA14moderate
- IsavuconazoleJ02AC05moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Trametinib in 10 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SwitzerlandMekinist 2 mg, FilmtablettenNovartis Pharma Schweiz AG
- SpainMEKINIST 2 MG COMPRIMIDOS RECUBIERTOS CON PELICULANovartis Europharm Limited
- IrelandMekinist 2 mg film-coated tabletsNovartis Europharm Limited
- IcelandMekinistNovartis Europharm Limited*
- NorwayMekinistNovartis Europharm Limited (1)
- PolandMekinistNovartis Europharm Limited
- SwedenMekinist 2 mg Filmdragerad tablettNovartis Europharm Limited
- United KingdomMekinist 0.5mg tabletsOriginalis B.V.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Mekinist, Spexotras
- Liechtenstein · Mekinist, Spexotras
- Norway · Mekinist, Spexotras
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/f4a8498e-dd47-4ade-af9d-69d5624678bb GET /v1/drugs/f4a8498e-dd47-4ade-af9d-69d5624678bb?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Filmomhulde tablet",
"route": "Oraal gebruik",
"soort": null,
"source": "cbg_meb",
"smpc_url": "https://www.ema.europa.eu/en/documents/product-information/mekinist-epar-product-information_nl.pdf",
"strength": null,
"atc_label": "Trametinib",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp113393",
"excipients": [
"CELLULOSE, MICROKRISTALLIJN (E 460(i))",
"CROSCARMELLOSE NATRIUM (E 468)",
"HYPROMELLOSE (E 464)",
"HYPROMELLOSE 2910 (3 - 15 mPa.s) (E 464)",
"IJZEROXIDE ROOD (E 172)",
"MACROGOL 400",
"MAGNESIUMSTEARAAT (E 470b)",
"MANNITOL (D-) (E 421)",
"NATRIUMLAURILSULFAAT",
"POLYSORBAAT 80 (E 433)",
"SILICIUMDIOXIDE (E 551)",
"TITAANDIOXIDE (E 171)"
],
"substances": [
"TRAMETINIBDIMETHYLSULFOXIDE"
],
"leaflet_url": null,
"authorised_at": "2014/06/30",
"procedure_number": "EMEA/H/C/002643",
"dispensing_status": "Uitsluitend recept",
"registration_number": "EU/1/14/931",
"additional_monitoring": "N"
}See everything about trametinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.